Cingulate (CING) Stock Price, News & Analysis

Company Overview

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD). The company is developing its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to deliver multiple doses of medication from a single tablet at predetermined times during the day.

Cingulate’s lead product candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate intended to provide a full day of ADHD symptom control with once-daily dosing. The company has also advanced additional product candidates, including CTx-1302, as part of its broader effort to develop stimulant-based ADHD therapies with differentiated dosing profiles.

Founded in 2017, Cingulate is headquartered in the Kansas City, Kansas, area and develops its therapies for potential use in the U.S. and other markets. The company is led by founder, Chairman and Chief Executive Officer Shane J. Schaffer. As a clinical-stage company, Cingulate’s product candidates remain subject to clinical development and regulatory review before they can be marketed.

Key Stats

• Today's Range: $4.59 to $4.97
• 50-Day Range: $4.52 to $5.87
• 52-Week Range: $3.16 to $11.89
• Volume: 171,891 shs
• Average Volume: 401,043 shs
• Market Capitalization: $70.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Moderate Buy

Cingulate Stock Analysis - MarketRank™

Cingulate scored higher than 37% of companies evaluated by MarketBeat, and ranked 713th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cingulate has a consensus price target of $27.00, representing about 460.2% upside from its current price of $4.82.

Amount of Analyst Coverage

Cingulate has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cingulate are expected to grow in the coming year, from ($2.19) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cingulate is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cingulate is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cingulate has a P/B Ratio of 15.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.50% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 13.52, which indicates bearish sentiment.

Change versus previous month

Short interest in Cingulate has recently increased by 10.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cingulate does not currently pay a dividend.

Dividend Growth

Cingulate does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.98

News Sentiment

Cingulate has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cingulate this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cingulate insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.30% of the stock of Cingulate is held by insiders.

Percentage Held by Institutions

41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CING
• CIK: 1862150
• Web: www.cingulate.com
• Phone: 913-942-2300
• Fax: N/A
• Employees: 14
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Cingulate: $27.00
• High Price Target: $52.00
• Low Price Target: $9.00
• Potential Upside/Downside: +460.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -238.40%
• Return on Assets: -128.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 3.50

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 15.55

Miscellaneous

• Outstanding Shares: 14,540,000
• Free Float: 13,771,000
• Market Cap: $70.08 million
• Optionable: Not Optionable
• Beta: -0.88